Becton, Dickinson and Company $BDX Shares Bought by KLP Kapitalforvaltning AS

Key Points

• KLP Kapitalforvaltning AS increased its stake in Becton, Dickinson and Company by 21.0%, adding 24,000 shares to its holdings, which are now valued at approximately $23.8 million.
• The company reported a 10.4% year-over-year increase in revenue, totaling $5.51 billion, and beat earnings expectations with $3.68 EPS compared to a consensus of $3.40.
• A recent quarterly dividend of $1.04 per share was paid, reflecting an annualized yield of 2.2% and a payout ratio of 74.82%.

KLP Kapitalforvaltning AS lifted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 21.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 138,380 shares of the medical instruments supplier's stock after purchasing an additional 24,000 shares during the period. KLP Kapitalforvaltning AS's holdings in Becton, Dickinson and Company were worth $23,836,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC increased its position in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after acquiring an additional 877 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Becton, Dickinson and Company by 50.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock worth $18,808,000 after acquiring an additional 27,581 shares in the last quarter. FORA Capital LLC purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth approximately $3,458,000. Foster Victor Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth approximately $6,406,000. Finally, GAMMA Investing LLC increased its position in shares of Becton, Dickinson and Company by 29.9% in the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock worth $744,000 after acquiring an additional 748 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $192.56 on Wednesday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $55.19 billion, a PE ratio of 34.63, a price-to-earnings-growth ratio of 1.50 and a beta of 0.25. The company has a 50 day moving average price of $189.41 and a two-hundred day moving average price of $186.83. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The firm had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company's revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were paid a $1.04 dividend. The ex-dividend date was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company's payout ratio is 74.82%.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company's stock, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,023 shares of company stock valued at $562,036 over the last 90 days. 0.36% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on BDX. Royal Bank Of Canada assumed coverage on shares of Becton, Dickinson and Company in a research report on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 target price on the stock. Piper Sandler reaffirmed a "neutral" rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research report on Saturday, September 27th. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Finally, Argus boosted their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of "Hold" and a consensus price target of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.